CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
Tislelizumab +5 moredrug
Likely dose
Paclitaxel 135 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04974047
NCT04974047Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Open-label, 2-Cohort Study to Investigate the Efficacy and Safety of PET Guided Neoadjuvant Treatment With Tislelizumab (BGB-A317) Plus Chemotherapy/Chemoradiotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

BeiGene·interventional·Posted Jul 23, 2021·Updated Dec 1, 2025

In Brief

A Phase 2 clinical trial evaluating Tislelizumab, Paclitaxel, and 4 other interventions for Resectable Esophageal Squamous Cell Carcinoma. Completed, enrolled 70 participants across 8 sites.

Detailed Summary

The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsResectable Esophageal Squamous Cell Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJul 23, 2021
Enrollment StartAug 17, 2021
Primary CompletionApr 17, 2023
Study CompletionOct 25, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.9 years ago

Interventions

Tislelizumabdrug

Administered intravenously on Day 1 of each 21-Day Cycle.

Paclitaxeldrug

135 mg/m\^2 administered intravenously on Day 1 of each 21-Day Cycle.

Cisplatindrug

80 mg/m\^2 administered intravenously on Day 1 of each 21-Day Cycle.

5-fluorouracildrug

1000 mg/m\^2 administered intravenously over Day 1 through 4 of each 21-Day Cycle.

Radiotherapyradiation

40 grays/20 fractions

Surgical resectionprocedure

Performed as indicated in the treatment arm.